Kynam Capital Management, LP

Position in ENGN — enGene Therapeutics Inc.

CIK 1907884 PRINCETON, NJ

Position in ENGN

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$792,089

-$8,448,011 QoQ

Shares Held

457,855

-66.3% QoQ

Ownership

0.683%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

#21

of 60 holders

Holding Since

Sep 2024

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Kynam Capital Management, LP holds $1,765,169,848 across 29 Biotechnology names. ENGN ranks #28 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	CLDX	Celldex Therapeutics, Inc.	5,322,908	$198,065,406
2	SNDX	Syndax Pharmaceuticals Inc	8,050,959	$175,993,963
3	PCVX	Vaxcyte, Inc.	2,922,335	$169,875,333
4	COGT	Cogent Biosciences, Inc.	3,667,097	$141,916,653
5	VERA	Vera Therapeutics, Inc.	2,890,059	$124,012,431
6	VRDN	Viridian Therapeutics, Inc.\DE	6,453,877	$118,557,720
7	TVTX	Travere Therapeutics, Inc.	2,000,000	$113,620,000
8	BEAM	Beam Therapeutics Inc.	2,840,792	$97,495,981

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$792,089	457,855	-66.3%	Shares	Sole	2026-08-14
2026-03-31	$9,240,100	1,356,843	-9.1%	Shares	Sole	2026-05-15
2025-12-31	$13,480,868	1,492,898	-70.1%	Shares	Sole	2026-02-17
2025-12-31	$13,480,868	1,492,898	—	Shares	Sole	2026-02-17
2025-09-30	$34,109,634	4,994,090	0.0%	Shares	Sole	2025-11-14
2025-06-30	$18,178,487	4,994,090	0.0%	Shares	Sole	2025-08-14
2025-03-31	$22,373,523	4,994,090	0.0%	Shares	Sole	2025-05-15
2024-12-31	$33,210,698	4,994,090	+187.6%	Shares	Sole	2025-02-14
2024-09-30	$11,459,098	1,736,227	—	Shares	Sole	2024-11-14
No filing history on record for this holder in this stock.